Lee Pharma to launch favipiravir under brand name Faravir at Rs 27 per tablet The nanomicellar formulation allows the CsA molecule to overcome solubility challenges, penetrate the eye’s … Sun Pharma introduces CEQUA SUPPORTTM Specialty Pharmacy programme to enable easy access for patients to obtain treatment Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has commercialised CEQUA (cyclosporine ophthalmic solution) 0.09 per cent in … There is a new pharmacological option for dry eye disease as Sun Pharma received FDA approval for Cequa (cyclosporine ophthalmic solution 0.09%).Cequa, which is indicated to increase tear production in patients with dry eye, provides the highest FDA-approved concentration of cyclosporine A (CsA) and is the first and only approved CsA product that incorporates a nanomicellar technology, according to Sun Pharma. Cequa (cyclosporine ophthalmic solution 0.09%), a calcineurin inhibitor immunosuppressant, is delivered with nanomicellar technology to improve the bioavailability and physicochemical stability of cyclosporine to improve ocular tissue penetration, the company said in a press release.Recent results from a multicenter, randomized, double-masked, vehicle-controlled phase 3 confirmatory study involving 744 subjects showed that the patients who were randomized to Cequa for 12 weeks had aThe company stated that Cequa was also found to be associated with statistically significant improvements in the key secondary endpoints, with improvements in both corneal and conjunctival staining compared to vehicle. The nanomicellar formulation allows the CsA molecule to overcome solubility challenges, penetrate the eye’s aqueous layer, and prevents the release of the active lipophilic molecule prior to penetration.In the phase 3 confirmatory trial on Cequa, after 12 weeks of treatment, as compared to vehicle, Cequa showed statistically significant improvement in the primary endpoint, Schirmer’s score (The nanomicellar formulation technology uses micelles, which are gelatinous aggregates of amphipathic (both hydrophobic and hydrophilic) molecules formed at a well-defined concentration. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the US Food and Drug Administration (FDA), is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people in the US. Atrimed Pharma claims breakthrough in molecule research for COVID-19 cure

“The availability of CEQUA will enable eye care professionals to further tailor dry eye treatment to individual patients’ needs.”Sun Pharma is also introducing CEQUA SUPPORT Specialty Pharmacy, a programme designed to enable commercially insured patients to easily obtain CEQUA. Sun Pharma hopes Cequa can wrest away a significant portion of the dry eye disease market from popular treatments such as Allergan’s blockbuster treatment Restasis or Shire’s Xiidra, which was approved in 2016. The editorial contents include: news, views, analysis and interviews, under four main segments: Market (The business of pharmaceuticals), Management (Insight for managing pharma), Research (Expertise for drug development) and Pharma Life (HR issues with a pharma focus). Cequa, which offers the highest concentration of cyclosporine for ophthalmic use approved by the FDA, is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). “The FDA approval of Cequa represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun’s Ophthalmics business. Warnings and Precautions. The small size of the nanomicelles facilitates entry into corneal and conjunctival cells, enabling delivery of high concentrations of CsA.“Dry eye disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated,” Abhay Gandhi, CEO, North America, Sun Pharma, said in a company news release.

CEQUA (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic use will be commercialized in the U.S. by Sun Ophthalmics, the branded ophthalmics division of Sun Pharma…

“The availability of Cequa will enable eye care professionals to further tailor dry eye treatment to individual patients’ needs.”“Keratoconjunctivitis sicca causes symptoms of burning, stinging, itching, grittiness, and dryness, underscoring the need for tolerable drug therapy with a fast onset of action,” Paul Karpecki, OD, FAAO, director of cornea services at the Kentucky Eye Institute in Lexington, said in the news release. CEQUA (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic use will be commercialized in the U.S. by Sun Ophthalmics, the branded ophthalmics division of Sun Pharma’s wholly owned subsidiary.